Synthesis 2012; 44(23): 3598-3602
DOI: 10.1055/s-0032-1317527
paper
© Georg Thieme Verlag Stuttgart · New York

A New Route to Roflumilast via Copper-Catalyzed Hydroxylation

Feng Ni
a   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, 1320 West Beijing Road, Shanghai 200040, P. R. of China
b   Shanghai Engineering Research Center of Pharmaceutical Process, 1320 West Beijing Road, Shanghai 200040, P. R. of China   Fax: +86(21)65312830   eMail: li.jianqi@sipi.com.cn
,
Jianqi Li*
a   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, 1320 West Beijing Road, Shanghai 200040, P. R. of China
b   Shanghai Engineering Research Center of Pharmaceutical Process, 1320 West Beijing Road, Shanghai 200040, P. R. of China   Fax: +86(21)65312830   eMail: li.jianqi@sipi.com.cn
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 27. August 2012

Accepted after revision: 14. Oktober 2012

Publikationsdatum:
06. November 2012 (online)


Preview

Abstract

A new route to Roflumilast, a selective phosphodiesterase type 4 (PDE 4) inhibitor, is described. The synthetic procedure starts from 4-hydroxy-3-iodobenzoic acid to access the key intermediate 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid via copper-catalyzed hydroxylation and utilizes amide coupling to accomplish the synthesis of Roflumilast in 80% overall yield.

Supporting Information